Abstract. Our previous study showed that the combination of a histone deacetylase (HDAC) inhibitor and an HIV protease inhibitor is effective against renal cancer cells. Because HDAC inhibition disrupts the chaperon function of heat shock protein (HSP) 90, we hypothesized that the combination of 17-allylamino-17-demethoxygeldanamycin (17-AAG), an inhibitor of HSP90, and the HIV protease inhibitor ritonavir would also act against renal cancer. The combination of 17-AAG and ritonavir induced apoptosis and inhibited the proliferation of renal cancer cells effectively. It also suppressed the expression of cyclin-dependent kinase 4 and cyclin D1, leading to the accumulation of the cells in the sub-G1 fraction. The expression of HSPs 27, 70 and 90 was increased by 17-AAG alone but reduced by 17-AAG combined with ritonavir. The combination decreased the expression of heat shock factor-1 (HSF-1), an HSP transcription factor, and this might be one of the mechanisms of the effect of the combination. We have also found that silencing of HSF-1 by siRNA inhibited the proliferation of renal cancer cells and that in surgically resected specimens the levels of HSF-1 expression in renal cancer tissue are higher than those in normal parenchyma. This is the first study showing the beneficial effect of combining 17-AAG and ritonavir and our data suggest that HSF-1 may be a novel therapeutic target in the treatment of renal cancer.
Introduction
Although recently introduced novel anticancer agents such as inhibitors of tyrosine kinase (1, 2) and the mammalian target of rapamycin (3) are promising against advanced renal cancer, new treatment approaches are needed because curative agents are not yet available.
Inhibition of heat shock protein 90 (HSP90) destabilizes the cancer cell's aberrant protein subset, leading to protein degradation by proteasomes (4) . The geldanamycin derivative 17-allylamino-17-demethoxy-geldanamycin (17-AAG) is the first HSP90 inhibitor to be used clinically (5) . It seems to be a promising anticancer agent with a novel mechanism of action, but a phase II clinical trial investigating the efficacy of 17-AAG found it not to be effective against renal cancer (6) .
We have previously shown that the combination of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) and the HIV protease inhibitor ritonavir is effective against renal cancer by inhibiting the HDAC function and expression, leading to extensive histone acetylation (7) . SAHA inhibits HDAC6, and ablation of HDAC6 has been shown to induce hyperacetylation of HSP 90, disrupting its chaperone function (8, 9) . We therefore thought that combining ritonavir with 17-AAG would be more effective against renal cancer because 17-AAG could inhibit HSP90 function more directly than SAHA does.
In the present study, we investigated the combined effect of 17-AAG and ritonavir against renal cancer by using renal cancer cell lines and found that the combination inhibited the renal cancer growth by inhibiting the expression of heat shock factor-1 (HSF-1), an HSP transcriptional factor. We also inferred from RNAi study results and the finding of higher expression of HSF-1 in surgically resected specimens that the expression of HSF-1 is associated with cell proliferation.
by the MTS assay (Promega, Madison, WI, USA) according to the manufacturer's protocol.
Colony formation assay. Caki-1 cells (5x10 3 ) were plated into 10-cm plates one day before being cultured for 24 h in media containing 0.05 µM 17-AAG and/or 50 µM ritonavir. They were then given fresh media and allowed to grow for 1 week before they were fixed with 100% methanol, stained with Giemsa's solution, and counted.
Apoptosis assay. Forty-eight hours after the cell culture in media containing 17-AAG and/or ritonavir, the induction of apoptosis was evaluated by Annexin V assay, measuring the cells in the sub-G1 fraction, and changes in the expression of survivin, X-linked inhibitor of apoptosis protein (XIAP), active caspase 3 and cleaved poly(ADP-ribose) polymerase (PARP) by western blot analysis.
Flow cytometry. Cells were plated in a 6-well culture plate and treated under the indicated conditions for 48 h. They were then washed with PBS and harvested by trypsinization. For cell cycle analysis, the harvested cells were resuspended in citrate buffer, stained with propidium iodide, and analyzed by flow cytometry. For Annexin V assay, the cells were stained with Annexin V according to the manufacturer's instruction (Beckman Coulter, Marseille, France) and then analyzed by flow cytometry. Data analysis was done by using CellQuest Pro Software (BD Biosciences, San Jose, CA, USA).
Western blot analysis. Equal amounts of protein from wholecell lysates were subjected to SDS-PAGE and transferred onto nitrocellulose membranes that were then probed with primary antibodies specific for anti-cyclin D1, anti-cyclin dependent kinase (CDK) 4, anti-HSF-1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-actin (Millipore, Billerica, MA, USA), anti-cleaved PARP, anti-HSP90, anti-HSP70, anti-HSP27 (Cell Signaling Technology, Danvers, MA, USA), anti-survivin (Alpha Diagnostic International, San Antonio, TX, USA), anti-XIAP, anti-acetylated histone (Abcam, Cambridge, UK). This probing was followed by treatment with horseradish-tagged secondary antibodies (GE Healthcare, Piscataway, NJ, USA) and visualization with chemiluminescence solutions (GE Healthcare).
Silencing of HSF-1 by siRNA transfection. Caki-1 cells were plated in 6-well (for western blot analysis) or 96-well (for MTS assay) culture plates one day before being given 100 nM HSF-1-specific siRNA or non-sense siRNA (Santa Cruz Biotechnology) that had been mixed with Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol. The cells were then cultured for 72 h and assayed for HSF-1 expression by western blot analysis and cell proliferation by MTS assay.
Expression of HSF-1 in surgically resected specimens.
Renal cancer tissue and normal renal parenchyma obtained at renal cancer surgery performed at our department was stored at -80˚C until use. Whole-cell lysates were obtained from 32 specimens and subjected to western blot analysis. The level of HSF-1 expression was semiquantified using the public domain NIH Image program and normalized to the level of actin expression. Relative HSF-1 density was calculated by dividing the HSF-1 level in cancer tissue by the HSF-1 level in normal parenchyma.
Statistical analyses. The statistical significance of observed differences between samples was determined using the MannWhitney U test (StatView software, SAS Institute, Cary, NC, USA). Differences were considered significant at p<0.05.
Results

Effect of combination of 17-AAG and ritonavir on cell proliferation.
MTS assay showed that 48-h treatment with combinations of 17-AAG and ritonavir inhibited the proliferation of renal cancer cells effectively ( Fig. 1A and B) . The combined effect seen when 25 µM ritonavir was given in combination seems to be synergistic. The combination of 17-AAG and 50 µM ritonavir also inhibited the clonogenecity of Caki-1 cells significantly (p<0.05) (Fig. 1C) .
Changes in the cell cycle and the expression of cell cycleassociated proteins.
To test the combined effect of 17-AAG and ritonavir on the cell cycle, we evaluated changes in the cell cycle and the expression of cell cycle-associated proteins. In Caki-1 and ACHN cells, 0.5 µM 17-AAG decreased the expression of cyclin D1 but ritonavir alone did not change the expression of either cyclin D1 or CDK4 ( Fig. 2A) . These changes were compatible with the observed changes in the cell cycle; that is, 17-AAG increased the number of the cells in the sub-G1 fraction and ritonavir had only slight effects on the cell cycle. Interestingly, the combination of 17-AAG and ritonavir greatly decreased the expression of both cyclin D1 and CDK4 in all the cell lines tested, leading to the accumulation of the cells in the sub-G1 fraction (Fig. 2B) .
Induction of apoptosis by the combination of 17-AAG and ritonavir.
To evaluate induction of apoptosis by the combination therapy, we first investigated the changes in the expression of antiapoptotic proteins, active caspase 3, and cleaved PARP in Caki-1 cells. The combination therapy decreased the expression of survivin and XIAP and increased the expression of cleaved PARP and active caspase 3 (Fig. 3A) . Flow cytometry also showed that the number of Annexin V-positive cells was increased synergistically by the combination of 17-AAG and ritonavir (Fig. 3B) .
17-AAG-induced HSP expression is suppressed by ritonavir in combination.
17-AAG inhibits HSP90 but it generally increases the expression of HSPs (10), which could attenuate the effect of 17-AAG. We therefore evaluated the HSP expression changes by the combination of 17-AAG and ritonavir (Fig. 4) . In Caki-1 Fig. 5A and B) . MTS assay results also confirmed this significant antiproliferative effect of HSF-1 silencing (Fig. 5C ). These results suggest that HSF-1 is associated with the proliferation of Caki-1 cells.
Expression of HSF-1 in surgically resected specimens. Because our in vitro experiment suggested the importance of HSF-1 expression in proliferation of renal cancer, we investigated the difference in the expression of HSF-1 between normal tissue and cancer tissue by using surgically resected specimens (Fig. 6, left) . HSF-1 expression was higher (relative HSF-1 level >1) in cancer tissue in 18 of 33 patients (Fig 6, right) , suggesting the importance of the HSF-1 expression in renal cancer.
Discussion
Inhibiting HSP90 is a novel and attractive approach to cancer treatment. 17-AAG is the first HSP90 inhibitor used clinically (5), but a clinical trial showed it not to be effective against renal cancer when administered alone (6) . Ritonavir is an HIV protease inhibitor widely used for treating HIV infection and has recently been found to have antitumor activity. It has been shown to inhibit the Akt (11) and NF-κB (12) signaling pathways, but the exact mechanism of its action is still unknown. We have recently shown that the combination of SAHA and ritonavir inhibits renal cancer growth synergistically by suppressing the expression and function of HDAC (7). Because inhibition of HDAC6 inhibits HSP90 function (8, 9) , we thought that the combination of 17-AAG and ritonavir would also be effective against renal cancer because 17-AAG directly inhibits the function of HSP90.
The combination of 17-AAG and ritonavir inhibited the growth of renal cancer cells effectively, leading to apoptosis. One mechanism of action would be perturbation of the cell cycle. In all the cell lines tested, the combination decreased the expression of cyclin D1 and CDK4 and increased the number of cells in the sub-G1 fraction. Previous studies showed that 17-AAG induced cell cycle arrest and apoptosis by downregulating cyclin D1 and CDK4 (10, 13) . Ritonavir was also reported to deplete CDKs 2, 4, and 6 and cyclin D1 (14) . Furthermore, both 17-AAG and ritonavir were shown to inhibit the transcription factor NF-κB (12, 15) and cyclin D1 is a target gene of NF-κB (16) . The combination of 17-AAG and ritonavir may thus act cooperatively to decrease the expression of cyclin D1 and CDK4 drastically, leading to apoptosis. Furthermore, in Caki-1 cells the combination decreased the expression of survivin and XIAP, which may be one mechanism of action causing apoptosis. Survivin and XIAP are both important antiapoptotic proteins in renal cancer. Survivin has been reported to be associated with the proliferation of renal cancer cells (17) and is a potential molecular target for treating renal cancer (18) (19) (20) . On the other hand, XIAP has been shown to be a prognostic marker in renal cancer (21) . The combination of 17-AAG and ritonavir is therefore attractive for treating renal cancer because it suppresses the expression of survivin and XIAP.
Although 17-AAG inhibits the function of HSP90, it generally increases the expression of HSPs (10), which could attenuate the effect of 17-AAG. Furthermore, in the present study the administration of 17-AAG alone increased the expression of HSPs 90, 70 and 27. The transcriptional regulation of different HSP genes is under the control of HSFs (22) . The function of HSF-1 is regulated by HSP90 and inhibition of HSP90 releases HSF-1 from the HSP90 complex, which results in its activation and translocation to the nucleus (23) . The combination suppressed the expression of HSF-1 and this would inhibit HSP induction by 17-AAG, enhancing 17-AAG activity. The exact mechanism of the regulation of HSF-1 expression, however, remains unknown. Further study is needed to clarify the mechanism of the regulation of HSF-1 expression and why ritonavir in combination decreased the HSF-1 expression.
Because HSP90 is required for the stability and function of a number of signaling proteins that promote the growth of cancer cells (24) , the expression of its transcription factor HSF-1 is also thought to be associated with cancer growth. There are, however, few studies directly focusing on the association between HSF-1 expression and cancer growth. Cai et al showed that increased expression of HSFs might render colon carcinoma cells resistant to the chemopreventive effects of butyrate (25) . According to our RNAi study, HSF-1 seems to play an important role in renal cancer growth. Furthermore, using surgically resected specimens, we have found that the expression of HSF-1 is higher in renal cancer tissue than in normal renal parenchyma. To our knowledge, this is the first study that showed HSF-1 may be a therapeutic target in the treatment of renal cancer. Targeting HSF-1 by, for example, using specific inhibitors of HSF-1 might also be effective against renal cancer.
In summary, the combination of 17-AAG and ritonavir inhibited renal cancer growth effectively and one mechanism of action might be the suppression of HSF-1 expression. HSF-1 may thus be a future novel therapeutic target in the treatment of renal cancer.
